8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________________________________________________________

FORM 8-K

_________________________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2025

_________________________________________________________________________________________________________________

Doximity, Inc.

(Exact Name of Registrant as Specified in Its Charter)

_________________________________________________________________________________________________________________

Delaware	001-40508	27-2485512
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
500 3rd St. Suite 510 San Francisco, CA 94107 (Address of principal executive offices, including zip code)
(650) 549-4330 (Registrant's telephone number, including area code)

_______________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, $0.001 par value per share	DOCS	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 10, 2025, Dr. Nathan Gross notified Doximity, Inc. (the “Company”) that he will step down from his role as Chief Strategy Officer to become an advisor to the Company, effective June 16, 2025. The advisory services will be provided under the terms of an Independent Contractor Agreement by and between the Company and Dr. Gross, dated June 13, 2025 (“Advisor Agreement”) until terminated by the terms of the Advisor Agreement. As consideration for his advisory services, restricted stock unit and option awards that were granted by the Company to Dr. Gross will continue to vest in accordance with the terms of the applicable award agreements through September 2025. Dr. Gross will receive no cash compensation for the advisory services pursuant to the Advisor Agreement. The foregoing summary of the Advisor Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the agreement. The Company expects to file a copy of the Advisor Agreement as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.

Item 7.01 – Regulation FD Disclosure

On June 13, 2025, the Company released a blog post relating to Dr. Gross’ transition to an external advisor to the Company. A copy of that blog post is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information provided in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 – Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Blog Post Regarding Transition of Role of Dr. Nathan Gross

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 13, 2025

DOXIMITY, INC.
By:	/s/ Anna Bryson
	Anna Bryson Chief Financial Officer

EX-99.1

Thank you, Nate!

After 15 wonderful years, our co-founder, partner, and pyramid topper (!), Dr. Nate Gross is moving on. He’ll remain an advisor here at Doximity, but not in a day-to-day role. We will miss him.

I first met Nate when he was co-founding Rock Health back in 2009. I recall being so impressed that he’d re-engineered his hospital’s pager software to run on his iPhone. He was then, and remains now, a human encyclopedia of digital health, a physician tech enthusiast who really understands how it all fits together.

That’s why we’re proud to keep Nate as an active advisor. He ain’t done fixing healthcare yet.

All the best, Nate.

Jeff

====

A farewell letter from Dr. Nate:

To my Doximity family,

Fifteen-and-a-half years ago, Jeff, Shari and I came together around a belief that physicians deserved better tools, and that it was possible to build a technology company that was unapologetically doctor-centric. That idea became Doximity, and, thanks to you, it has grown bigger than all of us. Building it with you has been the most meaningful chapter of my life.

1

Today I’m sharing a bittersweet update: I’ll be stepping down from my day-to-day role. I’ll remain an advisor and a proud member of the platform. This was an incredibly hard decision because I love what we do each day.

I’m as excited about Doximity’s future as I’ve ever been, and we’re in a terrific position to keep building great products:

•The products you’re building in workflow, news, and AI are transformative to the healthcare industry. And the product roadmap I’ve watched take shape over the past year convinces me Doximity has the ingredients to become a generational company while staying true to our “Physicians First” compass.

•Your discipline—in earning partners’ trust, insisting on win-wins for our members, and running lean and profitable—empowers us to continue to serve the medical profession and act on our vision.

•Most importantly, the team developing and leading this work is world-class and keeps leveling up every quarter.

That combination makes this a rare, genuinely good moment for a co-founder to pass the baton to immensely talented colleagues and create space for a new challenge.

To Jeff, Shari and our early team: thank you for believing in me, and in the idea that a platform for physicians could—and should—exist. To every Doxer past and present: your craft and relentless GSD spirit set the bar for what a mission-driven company can be, and it truly is special. To our investors, board, and partners: thank you for staying patient when quick wins beckoned, and for recognizing that doing right by doctors is a durable business model. To the physicians who invite us into their daily work, thank you for your candor and your trust; you remain our north star.

There is plenty more history to write. It’s a unique moment to raise the bar for what doctors can expect from technology. I’ll be cheering (loudly, with access to feedback buttons) from the stands, thrilled to watch what you ship next.

Thank you for letting me play a part in the story.

With deep gratitude and great optimism,

Nate

2

XML

Cover	Jun. 10, 2025
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jun. 10, 2025
Entity Registrant Name	Doximity, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40508
Entity Tax Identification Number	27-2485512
Entity Address, Address Line One	500 3rd St.
Entity Address, Address Line Two	Suite 510
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94107
City Area Code	650
Local Phone Number	549-4330
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A common stock, $0.001 par value per share
Trading Symbol	DOCS
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Entity Central Index Key	0001516513
Amendment Flag	false